

大中華科技(8032)夥中文大學設先進生科研究室

大中華科技(8032)於本年初推出冬蟲夏草保健食品草苓香，市場反應非常理想。沿於冬蟲夏草的保健食品至今已發展成一個系列，適合男女老幼各個不同的年齡層需要。大中華科技秉承中草藥現代化理念，積極從事中草藥現代化及標準化的研究。最近夥拍香港中文大學生物系，成立一個全港最先進的生物化學實驗室，藉以研究中藥對人體最有效及最直接的使用方法。

大中華科技最近向瑞典 Amersham Biosciences (安法瑪西亞生物技術有限公司)，訂購了最先進的蛋白組研究分析的質譜儀，及大規模 DNA(基因)分析系統，去進行基因及蛋白組的研究。這是亞洲科技公司中的突破，對亞太地區各地難以治療的疾病，將有嶄新的貢獻。

蛋白組是將人體細胞中的個別蛋白組獨立分析，將有病變傾向的蛋白組隔離，再加入中草藥，特別是真菌類的蛋白組，研究其對病變蛋白組的改善程度，從而找出治療的最佳方法。目前蛋白組的研究主要是對癌症的防治。

這個新的實驗室大大提高了對蛋白組的研究能力，使香港生物科學超越基因的研究，擠身於國際先進的蛋白組研究，亦大大縮減了分析所需的時間。大中華科技計劃在未/來一年，投資二至三千萬元進行有關實驗。

大中華科技主席鄭潔賢表示，生物科技業務的發展首重研究，將精深博大的傳統中藥與科技結合，可為中醫藥提供科學理據。而新的蛋白組研究是世界先進水平，當實驗成功，就可為目前難於治療的疾病提供有效的治療方法，所產生的新藥將會成為公司的專利產品，其中的商機是難以估計的。所以公司在成功將保健食品生產標準化後，積極投資於中醫藥的研發。

鄭氏指出，蟲草蛋白組對人體變異蛋白組作用的研究，首年目標為二萬個，公司計劃將這兩萬個研究結果成立一個資料庫。這個資料庫將可減省每次的分析時間，只要將病者的變異蛋白組分析出來，再從資料庫中找尋有治療作用的蟲草蛋白組。鄭潔賢指出，只要確定一個蟲草蛋白組，對人體病變蛋白組有治療作用，其價值已是億計。當大中華擁有這個兩萬個研究結果的資料庫，就已足以成為全球醫學權威。

如有查詢請電：張小姐 2296-1177 / 2296-1288

Research & Development - Chinese Medicinal Fungal Proteomics Laboratory

The Group is also engaged in the study of the standardization of Chinese herbs and medicines. It has set up a research and development laboratory – Chinese Medicinal Fungal (CMF) Proteomics Laboratory, a collaboration with the Department of Biology of Chinese University of Hong Kong. This study of Proteomics enables the detection of abnormalities for protein profile in diseases and tissues and applies a TCM/fungal methodology to identify and treat certain life threatening diseases such as leukemia, renal cancer, pancreatic cancer, liver cancer and other generic diseases in which they are unique in this part of the Asia Pacific region.

- ▶ First Laboratory in Hong Kong to set up ETTAN MALDI-TOF/Pro High throughput Mass Spectrometer. The laboratory also houses a MAGABACE DNA sequence analyzer.
- ▶ Create and correlate Genomic and Proteomic databases for Chinese Medicinal Fungi
- ▶ Conduct systematic study of protein-protein interactions in various biological systems
- ▶ Establishment of a portal for Chinese Medicinal Fungal databases of DNA and proteins
- ▶ Identify novel Gene/protein sequences which may have therapeutic values for new drug development



Moreover, the Chinese Medicinal Fungal ("CMF") - Proteomics Laboratory, (a collaboration of GCTG with the Department of Biology, CUHK) is conducting a series of studies on fungal proteins with medicinal potential. In view of the SARS virus, Professor Dennis LO (the Coordinator of the Molecular SARS Study Group of CUHK) and Professor Ice Sai Ming NGAI (the Director of CMF-Proteomics Laboratory), are currently participating in the analysis of the protein structure of SARS. GCTG is in the process of acquiring additional state-of-the-art medical equipment known as "Solid Phase Peptide Synthesizer" to generate biologically active peptide fragment in order to perform all necessary biophysical assays on characterising of the structural and functional relationships among the SARS viral peptides and antibodies and "our goal is to ultimately develop a biologically active synthetic peptide based vaccine", says Professor Ice Sai Ming NGAI.

